Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for AZEK in a research note issued on ...

William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named managing directors John Ivey and B.T. Remmert as the ...

Equities researchers at William Blair decreased their Q1 2025 earnings per share estimates for shares of Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

William Blair reiterated a Market Perform rating on CBOE Holdings (NYSE:CBOE), following the company's latest earnings report. CBOE Holdings reported an adjusted EPS of $2.10, falling short of both ...

For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...

William Blair downgraded Sprinklr (CXM) to Market Perform from Outperform without a price target after the company announced a 15% global ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

William Blair last night initiated coverage of Rubrik (RBRK) with a Market Perform rating. While Rubrik’s growth runway “ooks long and its ...

William Blair reaffirmed a Market Perform rating on Kenvue Inc (NYSE:KVUE), a consumer health company with a market capitalization of $38.69 billion. According to InvestingPro data, the company ...